Introduction
Worldwide there is a declining trend in human reproductive health; with infertility a major clinical problem, affecting one in every six couples (Mascarenhas et al., 2012) . This has led to a rise in the number of couples seeking ART such as IVF. Unfortunately, however, even in developed countries such as Australia, these treatments remain expensive and have limited success, with fewer than one in five treatment cycles resulting in a live birth (Fitzgerald et al., 2017) .
Ovarian-related infertility disorders, such as primary ovarian insufficiency (POI), are challenging to diagnose and treat. Moreover, as female-factor infertility accounts for half the known causes of infertility, our inability to overcome these challenges underpins the low success rates of assisted reproductive technologies. This is increasingly apparent in women over 35 years of age, who have a <13.8% chance of live birth per ART cycle, but constitute 61.7% of ART users (Fitzgerald et al., 2017) . This is because, as women age, the number of developing gametes (oocytes) within their ovaries is gradually depleted. Importantly, there is limited evidence to indicate that these oocytes, once lost through the natural processes of ovulation or ovarian mediated cell-death (atresia), are ever replenished (Faddy, 2000; Horan and Williams, 2017) .
POI affects~1% of all women (Haller-Kikkatalo et al., 2015) , and is defined by the early onset of menopause, before age 40. POI patients exhibit symptoms including primary or secondary amenorrhoea and pubertal delay and are consequently diagnosed when they are already well into reproductive decline (Tucker et al., 2016) . This condition is caused by the depletion of oocytes from the ovary, either by a low number of primordial follicles (oocyte-containing follicles) established during embryonic development or an increased activation of these follicles for subsequent development (Shelling, 2010) . The exact aetiology for most cases of POI (90%) remains unknown, however genetic, autoimmune, iatrogenic and environmental causes are associated with the decreased ovarian reserve in some POI patients (Nelson, 2009; Huhtaniemi et al., 2018) .
An understanding of primordial follicle biology is necessary for the diagnosis and treatment of ovarian-related infertility disorders. In addition, the precise timing and specificity of primordial follicle activation is crucial in normal folliculogenesis for maintaining the ovarian reserve for the many decades until menopause (Reddy et al., 2010) . This is because primordial follicles are the reservoir for all developing oocytes, and the number of primordial follicles maintained within the ovaries, at any point, will dictate a woman's reproductive lifespan. At the primordial stage, oocytes are dormant and can remain arrested in prophase I for decades. Once activated, the follicle and its contained oocyte will begin to grow, and from this time, its fate is sealed. For 99.99% of activated follicles, atresia (ovary-mediated apoptosis) is the default pathway, with on average less than 400 of the original 4-7 million primordial follicles formed in the ovaries before birth destined for ovulation (Reddy et al., 2010; Wallace and Kelsey, 2010; Kelsey et al., 2012) . For women with POI, their primordial follicle number is significantly reduced and a common cause of this is accelerated follicle activation, resulting in higher rates of atresia (Nelson, 2009 ).
In the pre-pubertal ovary, follicle development operates independently of gonadotropins and primordial follicle activation is intrinsically controlled. A plethora of pathways regulate primordial follicle activation and quiescence, including the PI3K/AKT, PTEN, SDF1, KITL and FOXO pathways among others (Holt et al., 2006; Reddy et al., 2008; Pelosi et al., 2013) . Loss of PTEN and FOXO and inhibition of SDF1 results in simultaneous activation of primordial follicles, whereas PI3K and KITL are crucial for the proliferation events that are required for primordial follicle activation (Adashi et al., 2000; Holt et al., 2006; Hutt et al., 2006; Reddy et al., 2008; Pelosi et al., 2013) . Gene ablation studies in animal models suggest the interaction of multiple factors and that investigation of global signalling pathways is essential to understanding the molecular mechanisms underpinning follicular regulation. Given KIT's ability to activate the JAK-STAT signalling pathway (Zhang and Liu, 2015) , we have previously demonstrated JAK-STAT pathway involvement in early follicle development (Sutherland et al., 2010 (Sutherland et al., , 2012 Sobinoff et al., 2013) .
The JAK-STAT pathway is a highly conserved signal transduction pathway activated by cytokines (Kisseleva et al., 2002) . Extracellular ligand binding to specific transmembrane receptors initiates a phosphorylation cascade involving Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) (Rawlings et al., 2004) . The suppressors of cytokine signalling (SOCS) are an example of STAT target genes, responsible for the negative regulation of the JAK-STAT pathway (Kile and Alexander, 2001; Alexander and Hilton, 2004) .
Recent studies have demonstrated that this pathway functions in mammalian folliculogenesis, both in vitro (Sutherland et al., 2012; Pastuschek et al., 2015) and in vivo (Hall et al., 2017) . Leukaemia Inhibitory Factor (LIF) treatment in cultured mouse ovaries results in the upregulation of STAT3 and SOCS4 protein (Sutherland et al., 2012) . JAK1, STAT3 and SOCS4 proteins localize to the granulosa cells of primordial and primary follicles (Sutherland et al., 2012) . LIF treatment also initiates the same pathway in human granulosa cells, with an increase of STAT3 expression (Pastuschek et al., 2015) . The JAK1-STAT3-SOCS4 pathway is conserved in the mare ovary in vivo, with JAK1 and STAT3 expression observed in the primordial follicles (Hall et al., 2017) . These studies have established that STAT3 is an essential STAT family member, involved in primordial follicle regulation, directed by JAK1 and negatively regulated by SOCS4 (Sutherland et al., 2012) .
Given that STAT activity is regulated by JAK expression and activation, we sought to determine the expression of all four JAK family members, namely TYK2 and JAK1-3, to evaluate the role of the JAK-STAT pathway in follicle development. The expression and localization of the JAK family during ovarian follicle development in the C57Bl/6 inbreed mouse strain was determined using a combination of qPCR, immunoblotting and immunolocalisation. This initial study indicated a critical role for JAK1 in follicle development. Further investigations of the underpinning cellular mechanisms were undertaken using biochemical in vitro inhibition and histological assessment of intact neonatal ovaries with the potent JAK inhibitor Ruxolitinib. Ovaries treated with Ruxolitinib demonstrated reduced JAK1 protein expression, upregulation of STAT3 and SOCS4 protein expression, increased apoptosis and accelerated primordial follicle activation. These findings present an opportunity to directly target the JAK-STAT pathway as a method of regulating the ovarian reserve.
Materials and Methods

Institutional animal care and use
C57Bl/6 mice were supplied by the University of Newcastle Animal Services Unit and all experiments involving the use of animals were conducted in accordance with the Institutes' Animal Care and Ethics Committee guidelines.
Mice
Mice were sacrificed at the following ages: post-natal days one (PND1), four (PND4), eight (PND8), as well as at 6 weeks (6WK) and 7 months (7MTH). Mice were housed under a controlled lighting regime (16 L: 8D) at 21-22°C and supplied with food and water ad libitum. Prior to dissection, animals were euthanized via CO 2 inhalation. Neonatal mice (PND1, PND4 and PND8) were euthanized by asphyxiation with carbon dioxide, followed by decapitation. Ovaries were collected immediately after euthanasia.
RNA extraction and qPCR
Ovaries were collected from female C57BL/6 mice at post-natal days one (PND1), four (PND4), eight (PND8), as well as at 6 weeks (6WK) and 7 months (7MTH). These ovarian ages corresponded to critical stages of development, specifically, primordial follicle endowment (PND1), primordial follicle activation (PND4), primary follicle transition (PND8), sexual maturation (6WK) and reproductive ageing (7MTH) (Franks and Payne, 1970; Sarraj and Drummond, 2012; Liu et al., 2013; Grive and Freiman, 2015) . Primordial follicle endowment occurs between E17.5 and PND3 and describes the encapsulation of oocytes by pre-granulosa cells (Findlay et al., 2015) . PND1 was chosen as the first time point as the majority of oocytes have been encapsulated and represent the maximal primordial follicle pool (Kerr et al., 2013; Findlay et al., 2015; Grive and Freiman, 2015) . By quantification of mRNA levels at these distinct stages, we could obtain a clear representation of which JAK members were more likely to have a functional role in follicle development.
Prior to RNA extraction, mouse ovaries were homogenized with a pestle and 20 G needle. RNA was extracted using an RNeasy-Mini Kit (Qiagen, Venlo, the Netherlands). Post-extraction, RNA was converted to cDNA using Reverse Transcription (RT) as previously described (Sutherland et al., 2018) . Quantitative PCR was performed on cDNA, with primer sequences and annealing temperatures listed in Table I . Reactions were performed on cDNA equivalent to 100 ng of total RNA for 40 amplification cycles. Data was normalized to Peptidylprolyl isomerase A (PpiA).
Protein extraction and immunoblot
Protein was extracted with Radioimmunoprecipitation assay (RIPA) buffer and quantified using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Twenty μg of protein/sample was separated by electrophoresis and transferred on to a nitrocellulose hybond C-Extra membrane (GE Healthcare, Little Chalfont, UK). Membranes were blocked and then incubated in anti-JAK1 antibody at a 1:1000 dilution (ab133666, Abcam, Cambridge, UK). Following incubation with a goat anti-rabbit HRPconjugated secondary antibody at a 1:1000 dilution (ab205718, Abcam), labelled proteins were visualized using an ECL Detection Kit (GE Healthcare). The membrane was then stripped using Western Re-probe (G-Biosciences, Maryland Heights, MO, USA) and reprobed for GAPDH (Sigma-Aldrich, St. Louis, Missouri, USA).
Immunolocalisation
Ovaries for immunolocalisation were subjected to Bouin's fixation for 4 h, washed in 70% ethanol, paraffin embedded and serially sectioned (4 μm thick) on to plain slides (three sections per slide). Sections were deparaffinised in xylene and rehydrated in ethanol. Heat mediated antigen retrieval was performed by boiling slides for 20 min in 10 mM sodium citrate buffer (pH 6). Once slides had returned to room temperature, sections were probed with the anti-JAK1 antibody at a 1:50 dilution (ab47435) (Abcam) and incubated overnight at 4°C. After washing, sections were incubated with the secondary antibody Alexa Fluor 555 goat anti-rabbit IgG at a 1:100 dilution (A-21428) (Thermo Fisher Scientific) for 2 h at room temperature. Slides were counterstained with 4′-6-Diamidino-2-phenylindole (DAPI) and mounted in antifade reagent Mowiol (13% w/v Mowiol4-88, 33% w/v glycerol, 66 mM Tris (pH 8.5), 2.5% w/v 1,4 diazobcyclo-[2.2.2]octane). Images were taken on an Axio Imager A1 fluorescent microscope (Carl Zeiss MicroImaging, Inc, Thornwood, NY) under fluorescent optics using an Olympus DP70 microscope camera (Olympus America, Center Valley, PA).
Bouin's fixed ovary sections were pre-treated with 20 μg/ml Proteinase K (Promega, Madison, WI, USA). TUNEL analysis was then performed using ApopTag Fluorescein In Situ Apoptosis Detection Kit (Merck, Darmstadt, Germany) according to the manufacturer's instructions. Slides were counter-stained with DAPI, mounted and imaged as described above.
Inhibitor study
The role of JAK1 in primordial follicle function was assessed utilizing the established technique of neonatal rodent ovary explant and in vitro culture (O'Brien et al., 2003; Sutherland et al., 2012) . PND2 mouse ovaries were incubated with Ruxolitinib, an established JAK inhibitor, for 48 h, and then collected for assessment. JAK inhibitor treated ovaries were histologically evaluated for follicle composition and apoptosis. Ovaries were collected from 4 x PND2 C57Bl/6 mice and placed on culture plate inserts in six-well tissue culture plate (Sarstedt, Germany) wells floating atop 1.5 ml DMEM/F12 medium containing 50 mg/ml foetal bovine serum (FBS), 1 mg/ml bovine serum albumin (BSA), 50 μg/ml ascorbic acid (MP Biomedicals, Solon, MO), 27.5 μg/ml insulin-transferrin-selenium, 2.5 mM L-glutamine and 5 U/ml penicillin/ streptomycin (Invitrogen, Carlsbad, CA, USA). Culture media contained either 12.5 μM Ruxolitinib (Santa Cruz Biotechnology, Dallas, TX, USA) or an equivalent volume of vehicle only control DMSO (one ovary from each mouse was assigned to each treatment). Ovaries were cultured for 48 h at 37°C and 5% CO 2 in air. This enabled the ovaries to develop in vitro to the equivalent of PND4.
Follicle counts
Following in vitro culture, ovaries were placed in Bouin's fixative for 4 h, washed in 70% ethanol, paraffin embedded and serially sectioned (4 μm thick) throughout the entire ovary, with every fourth slide counterstained with haematoxylin and eosin. Healthy oocyte-containing follicles where an oocyte nucleus was visible were classified as previously described (McLaughlin and Sobinoff, 2010) , and counted in every haematoxylin and eosin stained section. In summary, a primordial follicle was distinguished by all surrounding granulosa cells being flattened (of pre-granulosa morphology) while activated follicles showed at least one mature cuboidal granulosa cell present, but not all surrounding granulosa cells had changed morphology. Pre-antral stage was assigned to all full primary follicles (full layer of cuboidal granulosa cells) and any earlystage secondary follicles with a second layer of cuboidal granulosa cells.
Pixel intensity analysis
Pixel Intensity of immunofluorescence labelled primordial follicles in both treated and untreated ovaries was measured using Image J software of images taken with a 40x objective at the same excitation. By using the oval select tool, a minimum of 10 primordial follicles were identified within each ovary section (N = 4). Average pixel intensity was determined, and resultant untreated/treated values normalized to untreated. Results were analysed in GraphPad Prism seven using a two-tailed t-test.
Statistics
Statistical analysis was performed using two-tailed unpaired Student's t-tests (Fig. 3B) and two-way analysis of variance (ANOVA) with Tukey's post hoc multiple comparison (Figs 1A-E and 2B) using Graphpad Prism 7 software (San Diego, CA, USA). A P value of <0.05 was considered significant. Experiments were performed in triplicate using different mice each time, unless otherwise stated.
Results
Evaluation of janus kinase gene expression during post-natal ovary development
To determine which of the four Jak genes were most abundantly expressed during primordial follicle activation, we analysed mRNA expression across a developmental time-course. Quantitative PCR (qPCR) was performed on ovarian cDNA, isolated from each developmental stage, to assess the relative expression of all four Jak genes: Jak1, Jak2, Jak3 and Tyk2. Jak1 mRNA was constitutively expressed throughout all stages of ovarian follicle development, at significantly higher levels than all other isoforms (Fig. 1A) . During primary follicle growth, Jak2 mRNA was significantly increased at PND8, relative to PND1 (P = 0.016) and PND4 (P = 0.006). Upon reaching sexual maturity at 6WK, Jak2 mRNA had returned to levels similar to this in PND1 ovaries, but was found to be significantly increased in the ageing 7MTH ovary (P = 0.0327) (Fig. 1B) . Jak3 mRNA levels steadily decreased from PND1 to PND8 and 6WK (P = 0.0181 and 0.0324, respectively), with a significant increase in expression observed with age at 7MTH (P = 0.0006) (Fig. 1C) . Tyk2 mRNA remained unchanged across all developmental stages assessed (Fig. 1D) .
This data shows that each Jak family member has a distinctive mRNA expression profile within the mouse ovary during development. While Jak3 mRNA expression showed a decreasing trend between PND1 and PND4, this did not reach significance (P = 0.339) (Fig. 1C) . Interestingly, the level of Jak1 expression was significantly higher than all other members, with at least 7-fold greater levels observed across all developmental time-points (P ≤ 0.001) (Fig. 1E) . Jak1, as the most highly expressed mRNA, is likely to have a functionally important role within the ovary throughout the reproductive lifespan. Due to the high expression of JAK1 mRNA, JAK1 protein expression and localization was analysed during follicle development.
Analysis of JAK1 protein expression and localization during post-natal ovary development
Immunoblot analysis revealed stable protein expression in the ovary across neonatal development and at 7MTH, with a subtle, not significant (P = 0.06) decrease observed at sexual maturation (6WK) in the adult ( Fig. 2A ). This was supported by densitometry, with relative JAK1 expression compared to the stably expressed GAPDH (Fig. 2B ). JAK1 immunolocalisation was assessed in the ovary across distinct follicle stages in the neonate (PND4), adult (6WK) and ageing (7MTH) mouse ovary (for histological comparison see Supplementary Figure S1 ). In the neonatal ovary, JAK1 was localized to the nucleus and cytoplasm of granulosa cells at the primordial, activating and primary follicle stages, with faint expression detected in the oocyte cytoplasm of larger primary follicles (Fig. 2C) . JAK1 expression remained localized to the cytoplasm of granulosa cells in the adult and ageing ovaries with strong expression also observed in the cytoplasm of oocyte and granulosa cells within primary, pre-antral and antral follicles (Fig. 2C) . In addition, very high expression of JAK1 was identified in the ovarian stromal tissue, particularly at the 7MTH time point. A summary of relative JAK1 expression in all follicle stages and cell types is provided in Table II . The trending increase in total JAK1 protein in the 7MTH ovary immunoblot analysis, is likely due to high expression of JAK1 in the ovarian stroma, given there is a normal accumulation of stromal tissue with ovarian ageing (Briley et al., 2016) . The specific localization of JAK1 to primordial follicles provided justification for functional analysis of JAK-STAT signalling in post-natal follicle dynamics.
Functional assessment of JAK1 on primordial follicle activation via ruxolitinib inhibition
Visually, there was a clear increase in the number of growing (activated) follicles in JAK inhibitor treated ovaries as evidenced through H&E staining of ovarian cross-sections ( Fig. 3A and Supplementary  Fig. S2 ). Total ovary analysis, through follicle counting, confirmed a significant decrease in primordial follicle population in JAK inhibitor treated ovaries (P = 0.00002), which followed on to become a significant increase in the percentage of follicles undergoing activation (P = 0.0003) (Fig. 3B) . Importantly, this did not correlate to a significant increase in the percentage of follicles transitioning to the pre-antral stage of development.
To determine if the decrease in primordial follicle numbers and subsequent increase in activated follicles in JAK inhibitor treated ovaries was due to accelerated primordial follicle loss through apoptosis, TUNEL analysis was performed. TUNEL analysis demonstrated a clear Figure 1 QPCR Jak1-3 and Tyk2. Relative mRNA expression of Jak1 (A), Jak2 (B), Jak3 (C), Tyk2 (D) and all groups combined (E). MRNA expression within the mouse ovary was determined at post-natal day (PND)1, PND4, PND8, 6 weeks (WK) and 7 months (MTH). Expression was determined relative to the steady-state house-keeping gene Cyclophilin A (PpiA). Statistical significance (P < 0.05) within groups is indicated by different letters, with statistical significance between mRNA levels at each developmental stage indicated by: ***P ≤ 0.001, **P ≤ 0.01, n = 4. increase in the number of apoptotic cells within the ovaries subjected to JAK inhibitor treatment, in comparison to the untreated control group (Fig. 3C and Supplementary Fig. S2 ). It is important to note that the major cell type that stained positive for TUNEL were the somatic granulosa cells from activated follicles and not primordial follicles ( Supplementary Fig. S1 ).
We have previously established that activation of JAK1 in the neonatal mouse ovary, using the cytokine LIF, affects the expression of potential downstream pathway members: STAT3 and SOCS4 (Sutherland et al., 2012) . To establish the direct effects of JAK inhibition on the expression of JAK1, STAT3 and SOCS4 pathway members, protein immunofluorescence was performed on ovary sections.
The immunofluorescence analysis of tissue sections of JAK inhibited neonatal ovaries demonstrated a ubiquitous decrease in total JAK1 expression, as anticipated (Fig. 3D) . Interestingly, immunofluorescence analysis of STAT3 and SOCS4 demonstrated an increase in expression and localization of both proteins in JAK inhibited ovaries. Specifically, STAT3 was expressed most intensely in the oocyte cytoplasm in untreated ovaries, however, under JAK inhibition, STAT3 localization extended to include granulosa cells (Fig. 3D) . In untreated ovaries, SOCS4 expression was detected primarily in the nucleus of oocytes and granulosa cells, whilst in JAK inhibitor treated ovaries, overall SOCS4 protein expression was upregulated and coupled with a shift to localization in both the nucleus and cytosol of oocytes and granulosa cells (Fig. 3D) . The variations in STAT3 and SOCS4 expression in inhibitor treated ovaries were quantitatively validated through pixel intensity analysis which confirmed a significant increase in total fluorescence of both STAT3 (x1.29-fold increase, P < 0.05) and SOCS4 (x2.29-fold increase, P < 0.05) in primordial follicles. Combined, this data demonstrates that JAK1 inhibition positively regulates the expression of STAT3 and SOCS4 in the neonatal mouse ovary (Fig. 4) .
Discussion
Female infertility, caused by prematurely aged ovaries with reduced follicle populations and compromised oocytes, is both challenging to diagnose and treat due to the limited capabilities of current assisted reproductive technologies. Detailed knowledge of ovary follicle Figure 2 JAK1 protein expression and localization. The JAK1 antibody recognized two protein bands as visualized using chemiluminescence of HRPconjugated secondary antibody; one at 140 kDa and the other at 133 kDa as shown in the representative blots (A). Our positive control (spleen) appeared at 133 kDa (data not shown). Consequently, the lower molecular weight 133 kDa ovary protein bands were analysed. The blots were then stripped and re-probed with GAPDH (loading control), allowing these differences to be quantified using densitometry, with no significant difference in JAK1 protein levels n = 4 (B). Representative immunolocalisation of JAK1 was analysed in neonatal (PND4), adult (6WK) and ageing (7MTH) mouse ovary sections, n = 4 (C). Prominent JAK1 cytoplasmic expression was observed across all three developmental stages. Image labelling as follows: o = oocyte, g = granulosa cells, t = thecal cells, Pd = primordial, 1°= primary (activating), pA = pre-antral, A = antral, St-stroma. The scale bars for the first row of images is 50 μm and the second row of images is 20 μm. development, and in particular the regulation of primordial follicle activation, is critical to understanding female fertility. It is well established that primordial follicle regulation is a gonadotropin-independent process, regulated entirely by intrinsic ovarian signalling. We, and others, have identified a role for the JAK-STAT signalling pathway in oocyte and granulosa cell development (Anderson et al., 2009; Sutherland et al., 2012; Sobinoff et al., 2013; Starz-Gaiano, 2013, 2015; Pastuschek et al., 2015) . In this study, we have determined the crucial role of the JAK family in modulating the activation of primordial follicle regulation. We have identified Jak1 as the predominant transcript of the Jak family, expressed at the highest levels across all stages of ovarian development. Interestingly, JAK3 mRNA expression shows a decreasing trend at the early neonatal time-points and may potentially have a role in maintaining primordial quiescence. However, as high mRNA expression is indicative of high protein levels, we focused our investigations on the role of JAK1 as the principal bioactive JAK within the developing ovary.
Subsequent analysis of JAK1 protein expression and localization revealed that JAK1 was highly expressed during early-stage follicle development. JAK1 cellular expression was predominately within the granulosa cells of primordial and growing follicles. In these younger mouse ovaries, primordial follicles are just beginning to activate and transition to primary follicles, and granulosa cell-oocyte interactions are critical for this process (Kerr et al., 2013; Zhang et al., 2014; Zhang and Liu, 2015; Monniaux, 2016) . The detection of high expression of JAK1 in the granulosa cells of primordial and growing follicles of young and adult ovaries suggests a potential role for JAK1 in primordial follicle activation.
To determine if JAK1 served a functional role in primordial follicle regulation, we conducted an in vitro inhibition study in mouse neonatal ovary explants, using the JAK inhibitor Ruxolitinib. Ruxolitinib is a potent and selective JAK1 inhibitor (Mesa, 2010) currently approved for use in the treatment of the bone marrow disorders, myelofibrosis (Verstovsek et al., 2017) and polycythemia vera (Vannucchi et al., 2015) . Ruxolitinib also inhibits JAK2, with decreased efficacy in comparison to JAK1 (Quintas-Cardama et al., 2010) . Ruxolitinib has very minimal binding capacity for JAK3, with a greater than 130-fold selectivity for JAK1 and JAK2 versus JAK3 (Quintas-Cardama et al., 2010) . Furthermore, Jak2 and Jak3 mRNA had limited expression in the mouse ovary, particularly at the neonatal stages of follicle development, thus any effect of Ruxolitinib on primordial follicle activation was unlikely to be mediated via these isoforms. Future studies on the importance of other JAK family members, particularly JAK3, could be performed using the specific JAK3 inhibitor RB1 (Pei et al., 2018) .
Histomorphological analysis of 48 h cultured ovaries revealed that Ruxolitinib inhibition of JAK in vitro resulted in accelerated primordial follicle activation and increased follicle atresia through apoptosis, modelling the phenotype of early premature ovarian insufficiency. Furthermore, comparison of protein localization of JAK1, STAT3 and SOCS4, suggested a role for JAK1 in the regulation of these two downstream pathway members. Interestingly, despite a clear reduction in JAK1 protein expression in inhibitor treated ovaries, both STAT3 and SOCS4 were upregulated, with increased expression correlated to a prominent shift in localization to the nucleus and cytoplasm of granulosa cells.
In other biological systems, JAK1 has been previously shown to phospho-activate STAT3 protein (Justicia et al., 2000; Murray, 2007; Song et al., 2011) . Contrastingly, in our JAK inhibitor model, we identified an increase in STAT3 total protein. Although considered a key modulator (Hirano et al., 2000; Zhang et al., 2000) , JAK1 is not the only activator of STAT3 and we hypothesize that there may be a compensatory mechanism controlling STAT3 regulation in the absence of JAK1, responsible for its upregulation (Fig. 4) . To confirm this hypothesis, detailed analysis of alternative STAT3 activators would be necessary (Chung et al., 1997; Yuan et al., 2005) , including the bioactivity of other JAK family members and similar kinases (Song et al., 2003) . Furthermore, we have assumed that subcellular nuclear retention is indicative of STAT3 activation (Bhattacharya and Schindler, 2003) , but it would also be beneficial to determine relative STAT3 activity via analysis of its phosphorylated forms, tyrosine-705 and serine-727, in isolation.
Once activated, phosphorylated STATs form homo-or heterodimers and translocate to the nucleus to increase transcriptional initiation of target genes (Mertens and Darnell, 2007) . We have previously shown that STAT3 is responsible for the upregulation of its transcriptional target, Socs4 in the neonatal mouse ovary (Sutherland et al., 2012) . These findings are supported in our JAK inhibitor model, in which we observed a concomitant increase in granulosa cell expression of STAT3 and SOCS4. SOCS proteins prevent JAKs from activating STATs by direct and indirect interactions with tyrosine kinase SH2 domains necessary for driving this signalling cascade (Krebs and Hilton, 2001 ). In our inhibitor treated model, we propose that the observed upregulation of SOCS4 negatively feeds back to inhibit JAK1, which may in turn be causing a further decrease in JAK1 activation. To confirm this hypothesis, JAK1 phosphorylation status should be investigated alongside a shorter treatment period (24 h) to explore earlier signalling dynamics. STAT3 and SOCS4 proposed in our JAK inhibitor treatment study, further studies would be necessary to rule out any influence of JAK2. These findings contribute to the multitude of pathways currently implicated in primordial follicle quiescence and activation. Pathways including PI3K/AKT, PTEN, SDF1, KITL and FOXO, are key pathways involved in modulating primordial follicle activity (Adashi et al., 2000; Rawlings et al., 2004; Hutt et al., 2006; Reddy et al., 2008; Sobinoff et al., 2012; Pelosi et al., 2013; Zhang et al., 2014) . Cross-talk exists between the JAK-STAT and the PI3K signalling pathway in mammary glands, unveiling a molecular mechanism by which these pathways may interact in the ovary (Radler et al., 2017) . In conjunction with pathway crosstalk, KITL is known to activate signalling cascades through numerous pathways, most interesting being the PI3K-AKT and JAK-STAT pathways (Zhang and Liu, 2015) . Thus, our finding of key members of JAK-STAT signalling within the mammalian ovary provides links between the signalling pathways already characterized in moderating primordial follicle activation. Future studies analysing these findings in the context of other pathways would be extremely beneficial to characterize the global signalling patterns during primordial follicle activation.
In summary, this study has demonstrated JAK1 as the predominant JAK family member, expressed throughout mouse ovarian follicle development, distinctly in the granulosa cells of primordial and primary follicles of juvenile ovaries. When JAK1 protein is inhibited, STAT3 and SOCS4 are upregulated, primordial follicle activation is accelerated, and follicle loss through apoptosis is increased, modelling the human condition of premature ovarian insufficiency. These data demonstrate a key role for JAK1 in the maintenance and activation of primordial follicles, with potential to directly target the JAK-STAT pathway as a method of regulating the ovarian reserve and female fertility.
Supplementary data
Supplementary data are available at Molecular Human Reproduction online. Figure 3 JAK inhibitor analysis. Post-natal day (PND) two mouse ovaries were culture in 12.5 μM Ruxolitinib (JAK inhibitor) or vehicle only control DMSO (untreated) for 48 h, fixed and sectioned for histological assessment. JAK inhibited ovary sections showed an increase in activated follicles (*) (A), verified by representative follicle counts indicative of total follicle population. Scale bar indicates 100 μM, n = 4. (B). For counting, activated follicles are defined as having at least one pre-granulosa cell that has transitioned from squamous to cuboidal morphology, and have an increase in oocyte size (Holt et al., 2006; Hutt et al., 2006) . Statistical analysis of primordial follicles (P = 0.000024), activating (P = 0.00033) and pre-antral (P = 0.0823). In situ apoptosis via TUNEL analysis indicated an increase in granulosa cell apoptosis under Ruxolitinib inhibition. Scale bar indicates 50 μM, n = 4. (C). Representative immunolocalisation of JAK1, STAT3 and SOCS4 revealed loss of JAK1 protein expression and increased STAT3 and SOCS4 protein expression in Ruxolitinib (JAK inhibitor) treated ovaries. Image labelling as follows: o = oocyte, g = granulosa cells, Pd = primordial, 1°= primary (activated). Scale bar indicates 50 μM, n = 4. 
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